press release archive

Current \| 2007 \| 2006 \| 2005 \| 2004 \| 2003 \| 2002 \| 2001 \| 2000 \| 1999 \| 1998 \| 1997
12/6/2007		Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer

11/14/2007		Merck Serono Exercises Option to Rigel’s R763/AS703569 and Aurora Kinase Inhibitors in the Japanese Territory

11/6/2007		Rigel Announces Third Quarter 2007 Financial Results

8/7/2007		Rigel Announces Second Quarter 2007 Financial Results

7/12/2007		Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies

5/10/2007		Rigel Announces First Quarter 2007 Financial Results

5/2/2007		Rigel Announces Pricing of Public Offering of Common Stock

4/30/2007		Rigel Announces Offering of 5,000,000 Shares of Common Stock

4/16/2007		Rigel To Present New Research Programs at AACR Meeting

4/11/2007		Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

3/27/2007		Rigel Ubiquitin Ligase Program Identifies Molecules with Anti-HIV Activity

2/13/2007		Rigel Announces Initiation of Phase 1 Study Evaluating R763 in Hematological Malignancies

2/6/2007		Rigel Announces Fourth Quarter and Year End 2006 Financial Results

1/25/2007		Rigel Appoints Bradford S. Goodwin to Board of Directors

1/8/2007		Rigel Announces Initiation Of Phase II Study Evaluating R788 In Immune Thrombocytopenic Purpura (ITP)


© 2013 Rigel \| privacy \| disclaimer \| Follow Us On:	contact us \| site map \| search